AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the Clinic
Summary
AIRNA Raises Oversubscribed $60 Million Financing to Advance New Class of RNA Editing Medicines and Progress Best-in-Class AATD Program into the ClinicFinancing led by Forbion and includes participation from ARCH Venture Partners and a broad syndicate of world-class investors New funds will advance product candidate for the treatment of alpha-1 antitrypsin deficiency (AATD) into clinical trials Josh Brumm, General Partner at Forbion, to join AIRNA Board of DirectorsCAMBRIDGE, Mass. AIRNA launched with backing from ARCH Venture Partners to create a new class of RNA therapeutics based on seminal research published by academic co-founders Thorsten Stafforst and Jin Billy Li. AIRNA is developing medicines to address a wide array of diseases with high unmet need through its RESTORE+ platform, which optimizes oligonucleotide sequence, chemistry, and delivery for precise, efficient, and safe RNA editing. AIRNAs first product candidate is a potential best-in-class treatment for alpha-1 antitrypsin deficiency (AATD), a genetic condition implicated in severe lung and liver disease. Mr. Brumm was recently the CEO of Dyne Therapeutics, a Forbion portfolio company developing oligonucleotide-based medicines for patients with muscle diseases.